Table 1 Patient baseline demographics and characteristics (safety set).

From: Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

 

Berzosertib + gemcitabine (all doses), n = 50

Berzosertib + gemcitabine + cisplatin (all doses), n = 8

Sex, n (%)

  Male

28 (56.0)

4 (50.0)

  Female

22 (44.0)

4 (50.0)

Race, n (%)

  White

49 (98.0)

8 (100.0)

  Asian

1 (2.0)

0

  Median (range) age, years

62 (28–79)

52 (26–71)

Age category, n (%)

  <65 years

33 (66.0)

6 (75.0)

  ≥65 years

17 (34.0)

2 (25.0)

Primary tumour, n (%)

  NSCLC

6 (12.0)

1 (12.5)

  Pancreatic cancer

2 (4.0)

0

  Breast cancer

4 (8.0)

0

  Head and neck cancer

1 (2.0)

0

  Colorectal cancer

18 (36.0)

4 (50.0)

  Othera

19 (38.0)

3 (37.5)

WHO PS, n (%)

  0

15 (30.0)

3 (37.5)

  1

35 (70.0)

5 (62.5)

  Prior chemotherapy, n (%)

49 (98.0)

8 (100.0)

  Platinum-based chemotherapy

44 (88.0)b

8 (100.0)c

  Non-platinum-based chemotherapy

49 (98.0)d

8 (100.0)e

  1. WHO PS World Health Organization performance status, NSCLC non-small-cell lung cancer.
  2. aOther did not include small-cell lung cancer or ovarian cancer.
  3. bTen (20%) patients received prior cisplatin; best response of complete response (n = 1), partial response (n = 3), stable disease (n = 3), progressive disease (n = 2) and not available (n = 1).
  4. cTwo (25%) patients received prior cisplatin; best response of stable disease (n = 2).
  5. dFour (8%) patients previously received gemcitabine; best response to gemcitabine of partial response (n = 1), stable disease (n = 1), progressive disease (n = 1) and not available (n = 1).
  6. eNo patients received prior gemcitabine.
Back to article page